




RealRate

PHARMACEUTICAL 2022

Crescent Biopharma INC
Rank 212 of 471

GlycoMimetics, Inc.
Innovation Today, Healing Tomorrow.



The relative strengths and weaknesses of Crescent Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Crescent Biopharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Crescent Biopharma INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 312%, being 36% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	90,789
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,824
Liabilities, Non-Current	919
Other Assets	3,189
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	1,160
Property and Equipment	369
Research and Development	47,492
Selling, General and Administrative Expense	17,115

Output Variable	Value in 1000 USD
Assets	94,347
Liabilities	12,743
Expenses	64,607
Revenues	1,160
Stockholders Equity	81,604
Net Income	-63,447
Comprehensive Net Income	-63,447
BaseVar	86,428
ECR before LimitedLiability	214%
Economic Capital Ratio	312%